CSL share price drops 2.75 per cent despite lifting half-year profit

CSL failed to perform well on Tuesday as its share price dropped 2.75 per cent, despite lifting its half-year profit to $3.1 billion.

“Investors clearly wanted more from CSL’s results,” Sky News Business Reporter Edward Boyd said.

“One issue with CSL is its large inventory of blood plasma worth $US5.6 billion.

“The amount of products they make per litre of blood plasma is quite low.

“So if they can improve that, then they can expect a stronger result next time.”